Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma

November 4th 2025

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis

November 3rd 2025

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.

Evolving Role of TKIs and Antibody-Based Strategies Refines Ph-Positive ALL Management

November 3rd 2025

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

Dr Jhaveri on the Association Between ADCs and Ocular Toxicities in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses ocular toxicities that can be seen with the use of ADCs when treating patients with breast cancer.

Dr Stock on the Multifaceted Role of Molecular Testing in Ph+ ALL

October 31st 2025

Wendy Stock, MD, discussed the role of molecular testing in Ph-positive ALL and best practices for implementing this testing across clinical scenarios.

Dr Dent on the Efficacy of First-Line Dato-DXd in TNBC

October 31st 2025

Rebecca Dent, MD, MSc, FRCP, discusses data from the TROPION-Breast02 trial of frontline Dato-DXd vs chemotherapy in locally recurrent metastatic TNBC.

Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced Breast Cancer

October 31st 2025

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

October 31st 2025

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Personalized, Patient-Centered Strategies Shape the Evolving Management of Metastatic Pancreatic Cancer

October 31st 2025

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Dato-DXd Could Alter First-Line SOC in Immunotherapy-Ineligible TNBC

October 30th 2025

Rebecca Dent, MD, MSc, discusses data from the TROPION-Breast02 trial evaluating first-line Dato-Dxd in immunotherapy-ineligible triple-negative breast cancer

FDA Sets PDUFA Date for LNTH-2501 in Imaging of SSTR+ Neuroendocrine Tumors

October 30th 2025

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.

FDA Grants Orphan Drug Designation to DPTX3186 in Gastric Cancer

October 30th 2025

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

FDA Grants Orphan Drug Designation to Exosome-Based Therapy for Glioblastoma Multiforme

October 30th 2025

The FDA granted orphan drug designation to an exosome-based therapy for glioblastoma multiforme.

Dr Mehta on the Mitigation of Common Immunotherapy-Related Toxicities in Urothelial Cancer

October 30th 2025

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Vepugratinib-Based Therapy Displays Potential in Metastatic FGFR3+ Urothelial Cancer

October 29th 2025

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29th 2025

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29th 2025

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC

October 29th 2025

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

NEXT PAGE
PREVIOUS PAGE